Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
923032-37-5
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Bayer
gptkb:cancer gptkb:Ardea_Biosciences |
| gptkbp:hasMolecularFormula |
C16H13ClF2N2O3S
|
| gptkbp:hasUNII |
6QX8J8QK1U
|
| https://www.w3.org/2000/01/rdf-schema#label |
RDEA119
|
| gptkbp:mechanismOfAction |
MEK inhibitor
|
| gptkbp:molecularWeight |
402.8 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2105727
25154816 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
gptkb:refametinib
gptkb:BAY_86-9766 |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:bfsParent |
gptkb:refametinib
|
| gptkbp:bfsLayer |
7
|